Health Care & Life Sciences » Biotechnology | Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals Inc. | Ownership

Companies that own Aerie Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Wellington Management Co. LLP
5,325,289
11.78%
-44,062
0.06%
06/30/2018
Deerfield Management Company LP
3,891,051
8.6%
3,406,996
6.82%
07/23/2018
The Vanguard Group, Inc.
3,375,228
7.46%
240,533
0.01%
06/30/2018
Adage Capital Management LP
2,800,000
6.19%
-271,635
0.37%
06/30/2018
BlackRock Fund Advisors
2,784,032
6.16%
210,146
0.01%
06/30/2018
Partner Fund Management LP
2,754,798
6.09%
-114,676
2.93%
06/30/2018
OrbiMed Advisors LLC
1,884,100
4.17%
0
1.21%
06/30/2018
HealthCor Management LP
1,314,290
2.91%
114,290
2.33%
06/30/2018
Jennison Associates LLC
1,309,821
2.9%
-191,774
0.07%
06/30/2018
Invesco Advisers, Inc.
1,212,582
2.68%
63,589
0.04%
06/30/2018

About Aerie Pharmaceuticals

View Profile
Address
4301 Emperor Boulevard
Durham North Carolina 27703
United States
Employees -
Website http://www.aeriepharma.com
Updated 07/08/2019
Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and diseases of the eye. Its products include Rhopressa and Roclatan. The company was founded by David L.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.